{"nctId":"NCT03616899","briefTitle":"Safety and Efficacy of KPI-121 in Subjects With DED","startDateStruct":{"date":"2018-07-10","type":"ACTUAL"},"conditions":["Kerato Conjunctivitis Sicca"],"count":901,"armGroups":[{"label":"KPI-121 0.25% Ophthalmic Suspension","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: KPI-121 Ophthalmic Suspension"]},{"label":"Vehicle of KPI-121 0.25% Ophthalmic Suspension","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Vehicle"]}],"interventions":[{"name":"KPI-121 Ophthalmic Suspension","otherNames":[]},{"name":"Vehicle","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Have a documented clinical diagnosis of dry eye disease in both eyes\n\nExclusion Criteria:\n\n* Known hypersensitivity or contraindication to the investigational product(s) or components\n* History of glaucoma, IOP\\>21 mmHg at the screening or randomization visits, or being treated for glaucoma in either eye.\n* Diagnosis of: ongoing ocular infection; severe/serious ocular condition that in judgment of Investigator could confound study assessments or limit compliance; or have been exposed to an investigational drug within 30 days prior to screening.\n* In the opinion of the Investigator or study coordinator, be unwilling or unable to comply with study protocol or unable to successfully instill eye drops.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change From Baseline/Visit 2 (Day 1) in Ocular Discomfort Severity at Visit 4 (Day 15)","description":"Comparison of mean ocular discomfort severity between the KPI-121 0.25% ophthalmic suspension group and the vehicle group using a 0-100 visual analog grading scale where 0 was better and 100 was worse.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-13.58","spread":"19.379"},{"groupId":"OG001","value":"-8.91","spread":"17.579"}]}]}]},{"type":"PRIMARY","title":"Change From Baseline/Visit 2 (Day 1) Ocular Discomfort Severity at Visit 4 (Day 15) in the Subgroup of Participants With More Severe Ocular Discomfort","description":"Comparison of mean ocular discomfort severity between the KPI-121 0.25% ophthalmic suspension group and the vehicle group using a 0-100 visual analog grading scale where 0 was better and 100 was worse, in a sub-group of participants with more severe ocular discomfort at baseline.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-15.59","spread":"20.373"},{"groupId":"OG001","value":"-10.15","spread":"18.739"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline/Visit 2 (Day 1) in Bulbar Conjunctival Hyperemia at Visit 4 (Day 15)","description":"Comparison of mean bulbar conjunctival hyperemia between the KPI-121 0.25% ophthalmic suspension group and the vehicle group using a 0-4 grading scale. The grading scale was based on the Cornea and Contact Lens Research Unit Grading Scale where 0 = none, 1 = very slight, 2 = slight, 3 = moderate and 4 = severe.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.35","spread":"0.575"},{"groupId":"OG001","value":"-0.18","spread":"0.546"}]}]}]},{"type":"SECONDARY","title":"Change in Conjunctival Hyperemia Scores at Visit 4 (Day 15) by Alternate Assessor","description":"Comparison of mean bulbar conjunctival hyperemia between the KPI-121 0.25% ophthalmic suspension group and the vehicle group using a 0-4 grading scale. The grading scale was based on the Cornea and Contact Lens Research Unit Grading Scale where 0 = none, 1 = very slight, 2 = slight, 3 = moderate and 4 = severe.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.61","spread":"0.646"},{"groupId":"OG001","value":"-0.48","spread":"0.657"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline/Visit 2 (Day 1) in Ocular Discomfort Severity at Visit 3 (Day 8)","description":"Comparison of mean ocular discomfort severity between the KPI-121 0.25% ophthalmic suspension group and the vehicle group using a 0-100 visual analog grading scale where 0 was better and 100 was worse.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-8.05","spread":"15.009"},{"groupId":"OG001","value":"-5.83","spread":"15.176"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline/Visit 2 (Day 1) in Corneal Fluorescein Staining Score at Visit 4 (Day 15)","description":"Comparison of mean corneal fluorescein staining between the KPI-121 0.25% ophthalmic suspension group and the vehicle group using methods developed by the National Eye Institute (NEI) Dry Eye Workshop in evaluating 5 regions of the cornea (superior, inferior, nasal, temporal and central) using a 0-3 grading scale, where 0 = no visible staining, 1 = Mild, 2 = moderate and 3 = severe.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.53","spread":"0.800"},{"groupId":"OG001","value":"-0.43","spread":"0.739"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline/Visit 2 (Day 1) in Ocular Discomfort Severity at Visit 4 (Day 15) Using 7 Day Mean","description":"Comparison of mean ocular discomfort severity between the KPI-121 0.25% ophthalmic suspension group and the vehicle group using a 0-100 visual analog grading scale where 0 was better and 100 was worse.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-11.76","spread":"18.035"},{"groupId":"OG001","value":"-7.91","spread":"16.298"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":3,"n":449},"commonTop":["Instillation site pain","Dry eye","Eye pruritus","Eye irritation","Headache"]}}}